+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Stomach Cancer Treatment Market Size, Share & Trends Analysis Report by Treatment Type, by Disease Indication, by Route Of Administration, by Drug Class, by Distribution Channel, by Region, and Segment Forecasts, 2022-2030

  • PDF Icon

    Report

  • 140 Pages
  • August 2022
  • Region: Global
  • Grand View Research
  • ID: 5649386
Description Jump to:
The global stomach cancer treatment market size is expected to reach USD 11.2 billion by 2030, according to this report., expanding at a CAGR of 12.9% from 2022 to 2030. The increasing uptake of immunotherapy and targeted therapy, coupled with the launch of new drugs, is expected to fuel growth.

According to Globocan, the incidence of gastric cancer in 2020 was around 1.1 million, which is expected to increase to 1.42 million by 2030. The increasing knowledge regarding the molecular basis of the disease has led to a rise in the number of targeted drugs and immunotherapy drugs being developed and launched in the market. HER-2 targeted drugs such as Herceptin have been available in the market since 2010. Another targeted drug, Cyramza, which is a VEGF-targeting monoclonal antibody, has been available since 2014. EGFR and PD-1 targeted drugs and immunotherapies are currently being developed for the treatment of gastric cancer.

The approval and subsequent launch of drugs in the clinical pipeline are also expected to drive the gastric cancer therapy market. For instance, in March 2021, the NMPA approved Eli Lilly and Innovent Biologics’ drug Sintilimab, a PD-1 inhibitor, for the treatment of gastric or gastroesophageal junction adenocarcinoma in China. Furthermore, in May 2020, the U.S. FDA granted the orphan drug designation to Enhertu for the treatment of gastric cancers. Subsequently, in January 2021, the U.S. FDA approved Enhertu for the treatment of advanced or metastatic forms of the disease.

Patent expiry of key drugs such as Herceptin and subsequent launch of biosimilars are expected to restrain the growth of the gastric cancer therapy market. Additionally, lesser adoption of targeted therapy due to high costs might hamper the growth of the market. For instance, Cyramza was not considered cost-effective as compared to other drugs. It was rejected by NICE due to a lack of cost-effectiveness in England. Furthermore, the product was rejected for reimbursement in France due to a lack of additional benefits compared to the clinically relevant comparators.

Stomach Cancer Treatment Market Report Highlights

  • The targeted therapy treatment type segment held the second-largest revenue share in 2021 due to the robust clinical pipeline and approval of new products. For instance, in January 2021, the U.S. FDA approved Enhertu for the treatment of patients with metastatic or locally advanced HER-2 positive gastric cancers
  • By treatment type, immunotherapy is anticipated to witness the fastest growth during the forecast period due to the launch and adoption of PD-1 inhibitors such as Opdivo and Keytruda in the gastric cancer therapy market
  • By disease indication, the gastric cancer/gastroesophageal junction cancer segment is expected to maintain its lead during the forecast period due to the high prevalence of the disease and the availability of various products. The gastrointestinal stromal tumors (GISTs) segment is expected to grow due to the increasing number of product launches
  • Based on the distribution channel, the specialty and retail pharmacies segment dominated the gastric cancer therapy market in 2021. Targeted and immunotherapy drugs often have special requirements in terms of storage and logistics and are therefore distributed by specialty pharmacies
  • Asia Pacific is expected to maintain its dominance during the forecast period due to the high disease burden and research initiatives in the region. According to a Globocan report, Asia accounts for around 75.3% of all new cases of gastric cancer in 2020
  • Europe is anticipated to witness considerable growth during the forecast period owing to the increasing target patient population and approval of targeted and immunotherapy drugs

Table of Contents

Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates and Forecast Timeline
1.3 Research Methodology
1.4 Information Procurement
1.4.1 Purchased Database
1.4.2 Internal Database
1.4.3 Secondary Sources
1.4.4 Primary Research
1.4.5 Details of Primary Research
1.5 Information or Data Analysis
1.5.1 Data Analysis Models
1.6 Market Formulation & Validation
1.7 Model Details
1.7.1 Commodity Flow Analysis
1.7.1.1 Approach 1: Commodity Flow Approach
1.7.1.2 Approach 2: Country wise market estimation using bottom up approach
1.8 Global Market: CAGR Calculation
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.11.1 Objective 1:
1.11.2 Objective 2:
1.12 List of Tables
Chapter 2 Executive Summary
2.1 Market Summary
2.2 Market Segmentation
Chapter 3 Market Variables, Trends & Scope
3.1 Penetration and Growth Prospect Mapping
3.2 Regulatory framework
3.3 Stomach Cancer Treatment Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Robust product pipeline
3.3.1.2 Increasing prevalence of the disease
3.3.2 Market Restraint Analysis
3.3.2.1 Lack of reimbursement for currently approved targeted therapies
3.3.3 Market Opportunity Analysis
3.4 PESTEL Analysis
3.5 Porter’s Five Forces Analysis
3.6 Major deals and strategic alliances analysis
3.6.1 New product launch
3.6.2 Expansion
3.6.3 Partnership
3.6.4 Agreements
3.6 Pipeline Analysis
3.6.1 Analysis of key upcoming products
3.7 Epidemiology Analysis, by Country
3.8 Unmet Needs
Chapter 4 Treatment Type Business Analysis (Patient Share in %)
4.1 Stomach Cancer Treatment Market: Treatment Type Movement Analysis
4.2 Chemotherapy
4.2.1 Chemotherapy market estimates and forecast, 2018 - 2030
4.3 Immunotherapy
4.3.1 Immunotherapy market estimates and forecast, 2018 - 2030
4.4 Targeted Therapy
4.4.1 Targeted Therapy market estimates and forecast, 2018 - 2030
4.4 Radiation therapy & Surgery
Chapter 5 Disease Indication Business Analysis
5.1 Stomach Cancer Treatment Market: Disease Indication Movement Analysis
5.2 Gastric Cancer/Gastroesophageal Junction Cancer
5.2.1 Gastric Cancer/Gastroesophageal Junction Cancer market estimates and forecast, 2018 - 2030
5.3 Gastrointestinal Stromal Tumors
5.3.1 Gastrointestinal Stromal Tumors market estimates and forecast, 2018 - 2030
Chapter 6 Drug Class Business Analysis (Patient Share in %)
6.1 Stomach Cancer Treatment Market: Drug Class Movement Analysis
6.2 PD-1/PD-L1 inhibitors
6.2.1 PD-1/PD-L1 inhibitors market estimates and forecast, 2018 - 2030
6.3 HER2 antagonists
6.3.1 HER2 antagonists market estimates and forecast, 2018 - 2030
6.4 VEGFR2 antagonists
6.4.1 VEGFR2 antagonists market estimates and forecast, 2018 - 2030
6.5 Others
6.5.1 Others market estimates and forecast, 2018 - 2030
Chapter 7 Route of Administration Business Analysis
7.1 Stomach Cancer Treatment Market: Route of Administration Movement Analysis
7.2 Oral
7.2.1 Oral market estimates and forecast, 2018 - 2030
7.3 InjecTable
7.3.1 InjecTable market estimates and forecast, 2018 - 2030
Chapter 8 Distribution Channel Business Analysis
8.1 Stomach Cancer Treatment Market: Distribution Channel Movement Analysis
8.2 Hospital Pharmacies
8.2.1 Hospital Pharmacies market estimates and forecast, 2018 - 2030
8.3 Specialty & Retail Pharmacies
8.3.1 Specialty & Retail Pharmacies market estimates and forecast, 2018 - 2030
8.4 Others
8.4.1 Others market estimates and forecast, 2018 - 2030
Chapter 9 Regional Estimates & Trend Analysis
9.1. Regional Market Snapshot
9.1.1. North America
9.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
9.1.1.2. U.S.
9.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
9.1.1.3. Canada
9.1.1.3.1. Canada market estimates and forecast, 2018 - 2030 (USD Million)
9.1.2. Europe
9.1.2.1. Europe market estimates and forecast, 2018 - 2030 (USD Million)
9.1.2.2. U.K.
9.1.2.2.1. U.K. market estimates and forecast, 2018 - 2030 (USD Million)
9.1.2.3. Germany
9.1.2.3.1. Germany market estimates and forecast, 2018 - 2030 (USD Million)
9.1.2.4. Spain
9.1.2.4.1. Spain market estimates and forecast, 2018 - 2030 (USD Million)
9.1.2.5. France
9.1.2.5.1. France market estimates and forecast, 2018 - 2030 (USD Million)
9.1.2.9. Italy
9.1.2.9.1. Italy market estimates and forecast, 2018 - 2030 (USD Million)
9.1.3. Asia Pacific
9.1.3.1.Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
9.1.3.2. China
9.1.3.2.1. China market estimates and forecast, 2018 - 2030 (USD Million)
9.1.3.3. Japan
9.1.3.3.1. Japan market estimates and forecast, 2018 - 2030 (USD Million)
9.1.3.4. India
9.1.3.4.1. India market estimates and forecast, 2018 - 2030 (USD Million)
9.1.3.5. South Korea
9.1.3.5.1. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
9.1.3.9. Australia
9.1.3.9.1. Australia market estimates and forecast, 2018 - 2030 (USD Million)
9.1.4. Latin America
9.1.4. Latin America market estimates and forecast, 2018 - 2030 (USD Million)
9.1.4.1. Brazil
9.1.4.1.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
9.1.4.2. Mexico
9.1.4.2.1. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
9.1.4.3. Argentina
9.1.4.3.1. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
9.1.5. Middle East & Africa
9.1.5.1. MEA market estimates and forecast, 2018 - 2030 (USD Million)
9.1.5.2. South Africa
9.1.5.2.1. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
9.1.5.3. Saudi Arabia
9.1.5.3.1. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
9.1.5.4. UAE
9.1.5.4.1. UAE market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 10 Stomach Cancer Market - Competitive Analysis
10.1. Recent developments & impact analysis, by key market participants
10.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
10.3. Public Companies
10.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
10.3.2. Competitive Dashboard Analysis
10.3.2.1. Market Differentiators
10.4. Private Companies
10.4.1. List of key emerging companies’ /technology disruptors/innovators
10.4.2. Regional network map
10.4.3. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
10.5. Company Profiles
10.5.1. Eli Lilly and Company
10.5.1.1. Company Overview
10.5.1.2. Financial Performance
10.5.1.3. Product Benchmarking
10.5.1.4. Strategic Initiatives
10.5.2. F. Hoffmann-La Roche Ltd.
10.5.2.1. Company Overview
10.5.2.2. Financial Performance
10.5.2.3. Product Benchmarking
10.5.2.4. Strategic Initiatives
10.5.3. Pfizer Inc.
10.5.3.1. Company Overview
10.5.3.2. Financial Performance
10.5.3.3. Product Benchmarking
10.5.3.4. Strategic Initiatives
10.5.4. Novartis AG
10.5.4.1. Company Overview
10.5.4.2. Financial Performance
10.5.4.3. Product Benchmarking
10.5.4.4. Strategic Initiatives
10.5.5. Merck & Co., Inc.
10.5.5.1. Company Overview
10.5.5.2. Financial Performance
10.5.5.3. Product Benchmarking
10.5.5.4. Strategic Initiatives
10.5.6. Samsung Bioepis
10.5.6.1. Company Overview
10.5.6.2. Financial Performance
10.5.6.3. Product Benchmarking
10.5.6.4. Strategic Initiatives
10.5.10. Biocon
10.5.10.1. Company Overview
10.5.10.2. Financial Performance
10.5.10.3. Product Benchmarking
10.5.10.4. Strategic Initiatives
10.5.8. Mylan N.V.
10.5.8.1. Company Overview
10.5.8.2. Financial Performance
10.5.8.3. Product Benchmarking
10.5.8.4. Strategic Initiatives
10.5.9. Teva Pharmaceutical Industries Ltd.
10.5.9.1. Company Overview
10.5.9.2. Financial Performance
10.5.9.3. Product Benchmarking
10.5.9.4. Strategic Initiatives
10.5.10. Celltrion Healthcare Co., Ltd.
10.5.10.1. Company Overview
10.5.10.2. Financial Performance
10.5.10.3. Product Benchmarking
10.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (Patient Share in %, USD Million)
Table 4 Global Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (Patient Share in %, USD Million)
Table 5 Global Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 6 Global Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 7 Global Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 8 Global Stomach Cancer Treatment market, by Region, 2018 - 2030 (USD Million)
Table 9 North America Stomach Cancer Treatment market, by Country, 2018 - 2030 (USD Million)
Table 10 North America Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
Table 11 North America Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
Table 12 North America Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 13 North America Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 14 North America Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 15 U.S. Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
Table 16 U.S. Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
Table 17 U.S. Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 18 U.S. Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 19 U.S. Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 20 Canada Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
Table 21 Canada Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
Table 22 Canada Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 23 Canada Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 24 Canada Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 25 Europe Stomach Cancer Treatment market, by Country, 2018 - 2030 (USD Million)
Table 26 Europe Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
Table 27 Europe Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
Table 28 Europe Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 29 Europe Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 30 Europe Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 31 Germany Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
Table 32 Germany Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
Table 33 Germany Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 34 Germany Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 35 Germany Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 36 U.K. Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
Table 37 U.K. Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
Table 38 U.K. Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 39 U.K. Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 40 U.K. Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 41 France Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
Table 42 France Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
Table 43 France Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 44 France Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 45 France Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 46 Italy Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
Table 47 Italy Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
Table 48 Italy Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 49 Italy Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 50 Italy Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 51 Spain Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
Table 52 Spain Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
Table 53 Spain Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 54 Spain Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 55 Spain Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 56 Asia Pacific Stomach Cancer Treatment market, by Country, 2018 - 2030 (USD Million)
Table 57 Asia Pacific Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
Table 58 Asia Pacific Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
Table 59 Asia Pacific Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 60 Asia Pacific Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 61 Asia Pacific Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 62 China Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
Table 63 China Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
Table 64 China Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 65 China Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 66 China Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 67 Japan Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
Table 68 Japan Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
Table 69 Japan Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 70 Japan Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 71 Japan Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 72 India Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
Table 73 India Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
Table 74 India Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 75 India Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 76 India Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 77 South Korea Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
Table 78 South Korea Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
Table 79 South Korea Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 80 South Korea Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 81 South Korea Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 82 Australia Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
Table 83 Australia Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
Table 84 Australia Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 85 Australia Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 86 Australia Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 87 Latin America Stomach Cancer Treatment market, by Country, 2018 - 2030 (USD Million)
Table 88 Latin America Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
Table 89 Latin America Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
Table 90 Latin America Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 91 Latin America Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 92 Latin America Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 93 Brazil Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
Table 94 Brazil Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
Table 95 Brazil Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 96 Brazil Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 97 Brazil Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 98 Mexico Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
Table 99 Mexico Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
Table 100 Mexico Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 101 Mexico Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 102 Mexico Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 103 Argentina Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
Table 104 Argentina Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
Table 105 Argentina Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 106 Argentina Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 107 Argentina Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 108 Middle East & Africa Stomach Cancer Treatment market, by Country, 2018 - 2030 (USD Million)
Table 109 Middle East & Africa Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
Table 110 Middle East & Africa Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
Table 111 Middle East & Africa Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 112 Middle East & Africa Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 113 Middle East & Africa Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 114 South Africa Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
Table 115 South Africa Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
Table 116 South Africa Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 117 South Africa Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 118 South Africa Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 119 Saudi Arabia Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
Table 120 Saudi Arabia Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
Table 121 Saudi Arabia Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 122 Saudi Arabia Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 123 Saudi Arabia Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 124 UAE Stomach Cancer Treatment market, by Treatment Type, 2018 - 2030 (USD Million)
Table 125 UAE Stomach Cancer Treatment market, by Drug Class, 2018 - 2030 (USD Million)
Table 126 UAE Stomach Cancer Treatment market, by Route of Administration, 2018 - 2030 (USD Million)
Table 127 UAE Stomach Cancer Treatment market, by Disease Indication, 2018 - 2030 (USD Million)
Table 128 UAE Stomach Cancer Treatment market, by Distribution Channel, 2018 - 2030 (USD Million)
List of Figures
FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary Research Pattern
FIG. 4 Market Research Approaches
FIG. 5 Epidemiology - based market sizing & Forecasting
FIG. 6 Market Formulation & Validation
FIG. 7 Stomach Cancer Treatment Market, Market Segmentation
FIG. 8 Market Snapshot, 2021
FIG. 9 Market Trends & Outlook
FIG. 10 Market Driver Relevance Analysis (Current & Future Impact)
FIG. 11 Market Restraint Relevance Analysis (Current & Future Impact)
FIG. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
FIG. 13 Porter’s Five Forces Analysis
FIG. 14 Market Penetration Vs Growth Prospect Mapping, 2021
FIG. 15 Global Stomach Cancer Treatment Market:Treatment Type Movement Analysis
FIG. 16 Global Stomach Cancer Treatment Market, for Chemotherapy, 2018 - 2030 (Patient Share in %, USD Million)
FIG. 17 Global Stomach Cancer Treatment Market, for Immunotherapy, 2018 - 2030 (Patient Share in %, USD Million)
FIG. 18 Global Stomach Cancer Treatment Market, for Targeted drugs, 2018 - 2030 (Patient Share in %, USD Million)
FIG. 19 Global Stomach Cancer Treatment Market: Disease Indication Movement Analysis
FIG. 20 Global Stomach Cancer Treatment Market, for Gastric Cancer/Gastroesophageal Junction Cancer, 2018 - 2030 (USD Million)
FIG. 21 Global Stomach Cancer Treatment Market, for Gastrointestinal Stromal Tumors, 2018 - 2030 (USD Million)
FIG. 22 Global Stomach Cancer Treatment Market: Route of Administration Movement Analysis
FIG. 23 Global Stomach Cancer Treatment Market, for Oral, 2018 - 2030 (USD Million)
FIG. 24 Global Stomach Cancer Treatment Market, for InjecTable, 2018 - 2030 (USD Million)
FIG. 25 Global Stomach Cancer Treatment Market: Drug Class, Movement Analysis
FIG. 26 Global Stomach Cancer Treatment Market, for PD - 1/ PD - L1 inibitors, 2018 - 2030 (Patient Share in %, USD Million)
FIG. 27 Global Stomach Cancer Treatment Market, for HER2 Antagonists, 2018 - 2030 (Patient Share in %, USD Million)
FIG. 28 Global Stomach Cancer Treatment Market, for VEGFR Antagonists, 2018 - 2030 (Patient Share in %, USD Million)
FIG. 29 Global Stomach Cancer Treatment Market, for Others, 2018 - 2030 (Patient Share in %, USD Million)
FIG. 30 Global Stomach Cancer Treatment Market: Distribution Channel, Movement Analysis
FIG. 31 Global Stomach Cancer Treatment Market, for Hospital Pharmacies, 2018 - 2030 (USD Million)
FIG. 32 Global Stomach Cancer Treatment Market, for Specialty & Retail Pharmacies, 2018 - 2030 (USD Million)
FIG. 33 Global Stomach Cancer Treatment Market, for Others, 2018 - 2030 (USD Million)
FIG. 34 Regional Marketplace: Key Takeaways
FIG. 35 Regional Outlook, 2021 & 2030
FIG. 36 Global Stomach Cancer Treatment Market: Regional Movement Analysis
FIG. 37 North AmericaStomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 38 U.S. Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 39 Canada Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 40 Europe Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 41 Germany Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 42 U.K. Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 43 France Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 44 Italy Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 45 Spain Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 46 Asia Pacific Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 47 Japan Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 48 China Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 49 India Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 50 Australia Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 51 South Korea Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 52 Latin AmericaStomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 53 Brazil Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 54 Mexico Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 55 Argentina Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 56 Middle East and Africa Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 57 South Africa Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 58 Saudi Arabia Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)
FIG. 59 UAE Stomach Cancer Treatment Market, 2018 - 2030 (USD Million)

Companies Mentioned

  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • Samsung Bioepis
  • Biocon
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Celltrion Healthcare Co., Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages140
PublishedAugust 2022
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 4.25 Billion
Forecasted Market Value ( USD ) by 2030 $ 11.2 Billion
Compound Annual Growth Rate12.9%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Stomach Cancer Treatment Market by Treatment, Disease Indication, Drug Class, Route of Administration, Distribution Channel - Global Forecast 2025-2030 - Product Image

Stomach Cancer Treatment Market by Treatment, Disease Indication, Drug Class, Route of Administration, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Gastric Cancer Drugs Market by Molecule Type, Lines of Chemotherapy, Route of Administration - Global Forecast 2025-2030 - Product Image

Gastric Cancer Drugs Market by Molecule Type, Lines of Chemotherapy, Route of Administration - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
HER2-positive Gastric Cancer - Pipeline Insight, 2024 - Product Image

HER2-positive Gastric Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • 80 Pages
  • Global
From
Gastric Cancer - Pipeline Insight, 2024 - Product Image

Gastric Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • 550 Pages
  • Global
From
Gastric Cancer Therapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Gastric Cancer Therapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 112 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.